SuperworthArdelyx ARDX
- Market cap
- $767.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $450.9M
- +17% on a year ago
- Net margin
- −12.4%
- Free cash flow yield
- −2.3%
Ardelyx trades at 1.7× sales. Its trailing earnings are negative, so it has no PE. Revenue was $450.9M over the last twelve months, up 17% on a year earlier with a −12% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $56.4M+1031% | $34.4M−22% | $46M+305% | $73.2M+228% | $98.2M+74% | $116.1M+238% | $74.1M+61% | $97.7M+33% | $110.3M+12% | $125.2M+8% | $94.5M+28% | $120.9M+24% | |
| Cost of revenue | $7.7M+951% | $5.1M+61% | $7.1M+364% | $9.4M+170% | $15.7M+105% | $18.3M+260% | $12.3M+73% | $12.4M+31% | $4M−75% | $10.8M−41% | $4.8M−61% | $5.8M−54% |
| Gross profit | $48.7M+1045% | $29.3M−29% | $38.9M+296% | $63.8M+239% | $82.5M+69% | $97.9M+234% | $61.8M+59% | $85.3M+34% | $106.3M+29% | $114.4M+17% | $89.7M+45% | $115.1M+35% |
| R&D | $8.6M+16% | $9.5M+4% | $10.6M+16% | $12.8M+54% | $15.3M+77% | $13.7M+44% | $14.9M+41% | $15.7M+23% | $18.1M+18% | $22.9M+67% | $20.2M+35% | $26.1M+67% |
| SG&A | $32.7M+75% | $47.7M+142% | $53M+98% | $64.7M+138% | $65M+99% | $76.1M+59% | $83.2M+57% | $84M+30% | $83.6M+29% | $86.4M+14% | $102.3M+23% | $101.4M+21% |
| $7.4M | −$28M | −$24.7M−5% | −$13.6M−18% | $2.2M−70% | $8.1M | −$36.3M+47% | −$14.4M+6% | $4.7M+109% | $5.1M−37% | −$32.8M−10% | −$12.4M−14% | |
| Interest expense | $1.1M+25% | $1.7M+76% | $2.4M+129% | $3.3M+209% | $3.4M+203% | $4M+128% | $4.2M+78% | $4.4M+31% | $5.8M+73% | $5.8M+45% | $5.6M+34% | $5M+14% |
| Pre-tax income | $6.8M | −$28.5M | −$26.4M−1% | −$16.4M−4% | −$766K | $4.7M | −$40.3M+53% | −$19.1M+16% | −$867K+13% | −$400K | −$37.6M−7% | −$16.6M−13% |
| $200K | $333K | $121K+764% | $67K | $43K−79% | $35K−90% | $859K+610% | $1K−99% | $102K+137% | $7K−80% | $8K−99% | $110K+10900% | |
| Net income | $6.6M | −$28.8M | −$26.5M−1% | −$16.5M−4% | −$809K | $4.6M | −$41.1M+55% | −$19.1M+16% | −$969K+20% | −$407K | −$37.6M−9% | −$16.7M−12% |
| $0.03 | −$0.12 | −$0.11−15% | −$0.07−13% | $0.00 | $0.02 | −$0.17+55% | −$0.08+14% | $0.00 | $0.00 | −$0.15−12% | −$0.07−13% | |
| 227.9M+38% | 232.3M+21% | 233.1M+13% | 234.6M+9% | 235.9M+4% | 237.4M+2% | 238.6M+2% | 239.9M+2% | 241.9M+3% | 243.6M+3% | 245.9M+3% | 248.1M+3% |
Revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Gross profit: 26 periods, Q1 FY20 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Income tax: Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 10 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY17 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Ardelyx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ARDXArdelyx | $767.5M | n/m | n/a | 1.7× | +17% | −12.4% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| Peer median | $679.7M | 12.8× | 13.6× | 1.5× | +10% | 11.6% |
More on Ardelyx
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .